US OptionsDetailed Quotes
SLS241220P3000
- 0.00
- 0.000.00%
15min DelayClose Nov 25 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest3.00Strike Price0.00Turnover0.00%IV-156.41%PremiumDec 20, 2024Expiry Date1.83Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.67Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sellas Life Sciences Stock Discussion
Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Life Sciences Group (NASDAQ: SLS) has received Rare Pediatric Disease Designation (RPDD) from the FDA for Galinpepimut-S (GPS) in treating pediatric acute myeloid leukemia (AML). GPS, an immunotherapeutic targeting Wilms Tumor-1, is currently in a Phase 3 REGAL trial for adult AML patients, with an inte...
Sellas Receives EMA Orphan Drug Designation for Sls009 for Treatment of Peripheral T-Cell Lymphomas
No comment yet